全部照片(1)
About This Item
經驗公式（希爾表示法）:
C15H14N2O2
CAS號碼:
分子量：:
254.28
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
化驗
≥98% (HPLC)
形狀
powder
顏色
faintly yellow to dark yellow
溶解度
DMSO: ≥5 mg/mL
儲存溫度
room temp
SMILES 字串
NC(=O)Cc1cccc(c1N)C(=O)c2ccccc2
InChI
1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
InChI 密鑰
QEFAQIPZVLVERP-UHFFFAOYSA-N
基因資訊
human ... PTGS1(5742) , PTGS2(5743)
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery.
Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) used in opthamology.
Nepafenac, a prodrug of amfenac,[1] is used in the treatment of diabetic retinopathy.[2] It is metabolized to its active form through intraocular enzymatic hydrolysis.[1] Nepafenac has a molecular weight of 254.28 kDa and effectively penetrates through the cornea.[3] Its molecule structure enables nepafenac to possess better permeability. Nepafenac has a low inhibitory effect on cyclooxygenase.[3]
訊號詞
Warning
危險聲明
危險分類
Aquatic Acute 1 - Aquatic Chronic 1
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac
Walters T, et al.
Journal of Cataract and Refractive Surgery, 33(9), 1539-1545 (2007)
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology
Kern TS, et al.
Diabetes, 56(2), 373-379 (2007)
Retinal Pharmacotherapeutics: Retinal Pharmacotherapeutics (2015)
Eric Chen et al.
Clinical ophthalmology (Auckland, N.Z.), 4, 1249-1252 (2010-12-15)
The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macular degeneration. This was a retrospective, consecutive case series of patients with
Haley Shelley et al.
AAPS PharmSciTech, 19(6), 2554-2563 (2018-06-28)
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID), currently only available as 0.1% ophthalmic suspension (Nevanac®). This study utilized hydroxypropyl-β-cyclodextrin (HPBCD) to increase the water solubility and trans-corneal permeation of nepafenac. The nepafenac-HPBCD complexation in the liquid and solid states were
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
